Bergeron M G
Department of Microbiology, Laval University, Québec, Canada.
Med Clin North Am. 1995 May;79(3):619-49. doi: 10.1016/s0025-7125(16)30060-8.
Although prescribing an antibiotic for the treatment of pyelonephritis seems to be a relatively easy task, a close look at the available data is disturbing. Optimal therapies for the different clinical syndromes of pyelonephritis have not yet been defined. The high failure rate suggests that in pyelonephritis (bacteria protected in the medulla) as well as in bacterial endocarditis (bacteria sequestered in vegetations) and in infections in neutropenic patients (host defenses not necessarily operating in conjunction with antibiotics), it may be necessary to maintain bactericidal levels at the site of infection (infected medulla) to achieve cure. Pharmacodynamic studies suggest that TMP/SMX, quinolones, and aminoglycosides, which penetrate well the infected renal parenchyma and are not impaired by the local inflammatory process, should, with the exception of pyelonephritis in pregnancy, be preferred to beta-lactams as first-choice agents for the therapy of gram-negative pyelonephritis.
尽管开具抗生素治疗肾盂肾炎似乎是一项相对简单的任务,但仔细审视现有数据却令人不安。肾盂肾炎不同临床综合征的最佳治疗方法尚未明确。高失败率表明,在肾盂肾炎(细菌隐匿于髓质)、感染性心内膜炎(细菌藏匿于赘生物)以及中性粒细胞减少患者的感染(宿主防御不一定与抗生素协同作用)中,可能有必要在感染部位(感染的髓质)维持杀菌水平以实现治愈。药效学研究表明,甲氧苄啶/磺胺甲恶唑、喹诺酮类和氨基糖苷类药物能很好地穿透感染的肾实质且不受局部炎症过程影响,除妊娠期间的肾盂肾炎外,作为治疗革兰阴性菌肾盂肾炎的首选药物,应优先于β-内酰胺类药物。